Rationale and design for TIME: A phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarction.

@article{Traverse2009RationaleAD,
  title={Rationale and design for TIME: A phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarction.},
  author={Jay H. Traverse and Timothy D. Henry and Douglas E. Vaughan and Stephen G. Ellis and Carl J Pepine and James T. Willerson and David X M Zhao and Linda B. Piller and Marc S. Penn and Barry Byrne and Emerson C. Perin and Adrian Philip Gee and Antonis K. Hatzopoulos and David H. McKenna and John R. Forder and Doris A Taylor and Christopher R. Cogle and Rachel E. Olson and Beth C Jorgenson and Shelly L. Sayre and Rachel Westheimer Vojvodic and David J. Gordon and Sonia I Skarlatos and Lemuel A Moye' and Robert D. Simari},
  journal={American heart journal},
  year={2009},
  volume={158 3},
  pages={356-63}
}
Several previous studies have demonstrated that administration of autologous bone marrow-derived mononuclear cells (BMMNCs) improves cardiac function in patients after acute myocardial infarction (AMI). However, optimum timing of administration has not been investigated in a clinical trial. The Cardiovascular Cell Therapy Research Network was developed and funded by the National Heart, Lung, and Blood Institute to address important questions such as timing of cell delivery and to accelerate… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 42 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 23 references

Similar Papers

Loading similar papers…